TIF News

 

TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…

“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…

A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…

We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for 2021-2024 The extension of ΤIF’s official relations with WHO was…

Alla luce dei rapidi sviluppi scientifici nel campo della talassemia e dell’anemia falciforme con nuovi farmaci e trattamenti che promettono di rivoluzionare la gestione di queste malattie, la Federazione Internazionale…

In light of the tremendous scientific developments in the field of thalassemia and sickle cell disease (SCD) with new drugs and treatments that promise to revolutionize the management of these…

TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…

Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…